Climb Bio to Present at the 24th Annual Needham Virtual Healthcare Conference
Climb Bio (Nasdaq: CLYM) has announced its participation in the upcoming 24th Annual Needham Virtual Healthcare Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Climb Bio (Nasdaq: CLYM) has announced its participation in the upcoming 24th Annual Needham Virtual Healthcare Conference. The company's executive team will be presenting at this virtual event, which is scheduled to take place from April 7-10, 2025.
The presentation is specifically scheduled for April 10, 2025, at 8:45 a.m. ET. The format will include both a formal presentation and one-on-one investor meetings, providing opportunities for direct engagement with the company's leadership.
Details
News Market Reaction – CLYM
The recorded move for CLYM in the trading session of this news was -2.31%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WELLESLEY, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced that members of its executive team will participate at the 24th Annual Needham Healthcare Conference being held virtually April 7-10, 2025.
24th Annual Needham Virtual Healthcare Conference
Format: Presentation and one-on-one investor meetings
Date: April 10, 2025
Time: 8:45 a.m. ET
Webcast: Click here
About Climb Bio, Inc.
Climb Bio, Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s pipeline includes, budoprutug, an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases, and CLYM116, an anti-APRIL monoclonal antibody currently in IND-enabling studies for IgA nephropathy. For more information, please visit climbbio.com.
Investors
Chris Brinzey
ICR Healthcare
chris.brinzey@icrhealthcare.com
339-970-2843
Media
Jon Yu
ICR Healthcare
jon.yu@icrhealthcare.com
475-395-5375
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.